Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: Experience with 241 patients

Interactive Cardiovascular and Thoracic Surgery

Volumn 10, Issue 6, 2010, Pages 1009-1014

  Kanzaki, Ryu ^a   Higashiyama, Masahiko ^a   Maeda, Jun ^a   Okami, Jiro ^a   Hosoki, Takuya ^b   Hasegawa, Yoshihisa ^b   Takami, Motohisa ^b   Kodama, Ken ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Morinomiya Clinic PET Center   (Japan)

Author keywords

Follow up studies; Lung neoplasms; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; INCIDENTAL FINDING; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77954545556     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2009.227538     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, Hawkins RA. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993;72:82-90.
3. Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Krausz T, Jones T, Hughes JM. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-2689.
4. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004;125:1413-1423.
5. Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, van Zandwijk N, van Tinteren H, Smit EF. The value of [18F] fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003;39:151-157.
6. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605-1613.
7. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-382.
8. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, Yang DJ, Endo K, Podoloff DA. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-793.
9. Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N, Rigo P, Bartsch P. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J 1999;14:1376-1380.
10. Takenaka D, Ohno Y, Koyama H, Nogami M, Onishi Y, Matsumoto K, Matsumoto S, Yoshikawa T, Sugimura K. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assess-ment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol 2009 Apr 22. [Epub ahead of print].
11. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 975;70:606-612.
12. Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, Israel O. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-1646.
13. Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, Sybrecht GW, Kirsch CM. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21.
14. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-1481.
15. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. J Am Med Assoc 2001;285:914-924.
16. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med 2002;32:240-271.
17. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-139.
18. Quick reference table for medical fee points. Tokyo: Igakutsushinsya, 2006.